Skip to main content
. 2022 Jul 3;12(2):1137–1156. doi: 10.1002/cam4.4968

TABLE 1.

. Clinical characteristics of colorectal cancer patients within the Netherlands Cohort Study (NLCS, 1986–2006) according to mutational subgroup (n = 2344)

Total Mutational subgroups

All‐wild‐type

+pMMR

KRAS mut

+pMMR

KRAS mut

+PIK3CA mut

+pMMR

PIK3CA mut

+pMMR

BRAF mut Other p‐value *

BRAF mut

+pMMR

BRAF mut

+dMMR

Other

+pMMR

Other

+dMMR

Number of patients, n (%) 2344 851 (36.3) 580 (24.7) 173 (7.4) 124 (5.3) 147 (6.3) 134 (5.7) 218 (9.3) 117 (5.0)
Age at diagnosis in years, median (range) 74.0 (55.0–89.0) 74.0 (55.0–89.0) 74.0 (56.0–89.0) 74.0 (60.0–88.0) 72.0 (58.0–84.0) 75.0 (56.0–88.0) 76.0 (62.0–86.0) 73.0 (56.0–87.0) 74.0 (57.0–87.0) <0.001
Sex, n (%)
Men 1311 (55.9) 542 (63.7) 311 (53.6) 94 (54.3) 79 (63.7) 62 (42.2) 41 (30.6) 129 (59.2) 53 (45.3) <0.001
Women 1033 (44.1) 309 (36.3) 269 (46.4) 79 (45.7) 45 (36.3) 85 (57.8) 93 (69.4) 89 (40.8) 64 (54.7)
Tumor location, n (%)
Colon 1652 (70.5) 515 (60.5) 387 (66.7) 133 (76.9) 91 (73.4) 132 (89.8) 132 (98.5) 149 (68.4) 113 (96.6) <0.001
Rectosigmoid 239 (10.2) 116 (13.6) 74 (12.8) 13 (7.5) 11 (8.9) 3 (2.0) 1 (0.8) 20 (9.2) 1 (0.9)
Rectum 453 (19.3) 220 (25.9) 119 (20.5) 27 (15.6) 22 (17.7) 12 (8.2) 1 (0.8) 49 (22.5) 3 (2.6)
pTNM stage, n (%)
I 459 (19.6) 194 (22.8) 119 (20.5) 29 (16.8) 18 (14.5) 10 (6.8) 19 (14.2) 52 (23.9) 18 (15.4) <0.001
II 877 (37.4) 305 (35.8) 185 (31.9) 74 (42.8) 53 (42.7) 47 (32.0) 65 (48.5) 75 (34.4) 73 (62.4)
III 614 (26.2) 220 (25.9) 157 (27.1) 40 (23.1) 30 (24.2) 59 (40.1) 37 (27.6) 51 (23.4) 20 (17.1)
IV 330 (14.1) 102 (12.0) 105 (18.1) 27 (15.6) 18 (14.5) 27 (18.4) 10 (7.5) 35 (16.1) 6 (5.1)
Unknown 64 (2.7) 30 (3.5) 14 (2.4) 3 (1.7) 5 (4.0) 4 (2.7) 3 (2.2) 5 (2.3)
Tumor extension (pT), n (%)
T1 102 (4.4) 48 (5.6) 27 (4.7) 10 (5.8) 4 (3.2) 1 (0.7) 2 (1.5) 10 (4.6) <0.001
T2 439 (18.7) 181 (21.3) 116 (20.0) 23 (13.3) 16 (12.9) 13 (8.8) 17 (12.7) 53 (24.3) 20 (17.1)
T3 1511 (64.5) 522 (61.3) 373 (64.3) 117 (67.6) 89 (71.8) 101 (68.7) 94 (70.2) 129 (59.2) 86 (73.5)
T4 221 (9.4) 67 (7.9) 46 (7.9) 20 (11.6) 10 (8.1) 27 (18.4) 19 (14.2) 21 (9.6) 11 (9.4)
Unknown 71 (3.0) 33 (3.9) 18 (3.1) 3 (1.7) 5 (4.0) 5 (3.4) 2 (1.5) 5 (2.3)
Lymph node involvement (pN), n (%)
N0 1212 (51.7) 444 (52.2) 280 (48.3) 95 (54.9) 63 (50.8) 54 (36.7) 77 (57.5) 119 (54.6) 80 (68.4) <0.001
N+ 853 (36.4) 297 (34.9) 234 (40.3) 59 (34.1) 40 (32.3) 81 (55.1) 44 (32.8) 75 (34.4) 23 (19.7)
Unknown 279 (11.9) 110 (12.9) 66 (11.4) 19 (11.0) 21 (16.9) 12 (8.2) 13 (9.7) 24 (11.0) 14 (12.0)
Differentiation grade, n (%)
Well 198 (8.5) 79 (9.3) 57 (9.8) 15 (8.7) 11 (8.9) 10 (6.8) 4 (3.0) 17 (7.8) 5 (4.3) <0.001
Moderate 1528 (65.2) 597 (70.2) 381 (65.7) 122 (70.5) 86 (69.4) 69 (46.9) 66 (49.3) 150 (68.8) 57 (48.7)
Poor/undifferentiated 412 (17.6) 101 (11.9) 81 (14.0) 22 (12.7) 18 (14.5) 59 (40.1) 53 (39.6) 33 (15.1) 45 (38.5)
Unknown 206 (8.8) 74 (8.7) 61 (10.5) 14 (8.1) 9 (7.3) 9 (6.1) 11 (8.2) 18 (8.3) 10 (8.6)
Adjuvant therapy, n (%)
No 1830 (78.1) 654 (76.9) 434 (74.8) 142 (82.1) 94 (75.8) 121 (82.3) 121 (90.3) 158 (72.5) 106 (90.6) <0.001
Yes 494 (21.1) 186 (21.9) 139 (24.0) 31 (17.9) 29 (23.4) 26 (17.7) 13 (9.7) 59 (27.1) 11 (9.4)
Unknown 20 (0.9) 11 (1.3) 7 (1.2) 1 (0.8) 1 (0.5)

Abbreviations: pMMR, mismatch repair proficient; dMMR, mismatch repair deficient; TNM, tumor‐node‐metastasis; N0, no lymph node metastasis; N+ one or more lymph node metastases.

*

p‐value for the χ2 test, unless otherwise specified.

p‐value for the Kruskall–Wallis test.